Diabetes mellitus after living donor liver transplantation: data from mainland China.
Most reported data on posttransplantation diabetes mellitus (PTDM) are from Western countries with patients who underwent deceased donor liver transplantation. A retrospective study was performed to assess the prevalence and predictive factors of PTDM in the context of living donor liver transplantation (LDLT) in the Chinese population using the definition of PTDM proposed in 2003 by the World Health Organization and the American Diabetes Association. The prevalence of DM after LDLT in our study was 25% (21/84), and the incidence of PTDM was 14.9% (11/74) with 64% of cases diagnosed within 3 months after LDLT; 9.5% were observed to show impaired fasting glucose postoperatively. Multivariate analysis identified body mass index >or= 25 kg/m(2) before LDLT as the only independent risk factor for developing PTDM. Only one patient was operated for hepatitis C virus (HCV) infection. Hepatitis B virus (HBV)-related diseases were common in our study population, accounting for 78.6% of all patients. Both HCV and HBV infection status were not independent risk factors for developing PTDM. In addition, a greater tacrolimus trough blood level in the PTDM group versus no-DM group was observed at 3 months post-LDLT (11.03 ng/mL vs 4.87 ng/mL). The mean tacrolimus dose was not significantly different between the two groups. In conclusion, PTDM was prevalent among Chinese LDLT recipients.
Zhao
J
J
Liver Transplantation Division, Department of Surgery, West China Hospital, West China Medical School of Sichuan University, Chengdu, Sichuan Province, China.
Yan
L
L
Li
B
B
Zeng
Y
Y
Wen
T
T
Zhao
J
J
Wang
W
W
Xu
M
M
Yang
J
J
Ma
Y
Y
Chen
Z
Z
Wu
H
H
Wei
Y
Y
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D002681:China; D003920:Diabetes Mellitus / Q000097:blood / Q000209:etiology*; D005260:Female; D018149:Glucose Intolerance / Q000097:blood / Q000209:etiology; D006509:Hepatitis B / Q000601:surgery; D006526:Hepatitis C / Q000601:surgery; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D015994:Incidence; D016031:Liver Transplantation / Q000009:adverse effects*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D011183:Postoperative Complications / Q000209:etiology*; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D016559:Tacrolimus / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
D001786:Blood Glucose; D007166:Immunosuppressive Agents; D016559:Tacrolimus